Certain Series A Non-Voting, Convertible Preferred Stock of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024.
May 26, 2024
Share
Certain Series A Non-Voting, Convertible Preferred Stock of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024. These Series A Non-Voting, Convertible Preferred Stock will be under lockup for 90 days starting from 27-FEB-2024 to 27-MAY-2024.
Details:
Executive officers and directors have agreed, for a period of three months from the date of this prospectus supplement, with respect to officers and directors, and 45 days, with respect to the company not to, directly or indirectly, offer to sell, sell, pledge or otherwise transfer or dispose of any of shares of (or enter into any transaction or device that is designed to, or could be expected to, result in the transfer or disposition by any person at any time in the future of) common stock, enter into any swap or other derivatives transaction that transfers to another, in whole or in part, any of the economic benefits or risks of ownership of shares of common stock, make any demand for or exercise any right or cause to be filed a registration statement, including any amendments thereto, with respect to the registration of any shares of common stock or securities convertible into or exercisable or exchangeable for shares of common stock or any other of securities or publicly disclose the intention to do any of the foregoing, subject to customary exceptions, without the prior written consent of the representative.
Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It is focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its lead product and focus is on the development and commercialization of ONP-002 for the treatment of mTBI.